nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ADRB1—stomach cancer	0.368	0.543	CbGaD
Nadolol—ADRB2—stomach cancer	0.31	0.457	CbGaD
Nadolol—ABCB1—Mitomycin—stomach cancer	0.0907	0.581	CbGbCtD
Nadolol—ABCB1—Irinotecan—stomach cancer	0.0233	0.149	CbGbCtD
Nadolol—ABCB1—Docetaxel—stomach cancer	0.017	0.109	CbGbCtD
Nadolol—ABCB1—Doxorubicin—stomach cancer	0.0127	0.0814	CbGbCtD
Nadolol—ABCB1—Methotrexate—stomach cancer	0.0123	0.0789	CbGbCtD
Nadolol—Pirbuterol—ADRB1—stomach cancer	0.000734	0.1	CrCbGaD
Nadolol—Levobunolol—ADRB1—stomach cancer	0.000654	0.0896	CrCbGaD
Nadolol—Pirbuterol—ADRB2—stomach cancer	0.000617	0.0845	CrCbGaD
Nadolol—Carteolol—ADRB1—stomach cancer	0.000556	0.0762	CrCbGaD
Nadolol—Levobunolol—ADRB2—stomach cancer	0.00055	0.0753	CrCbGaD
Nadolol—Bupranolol—ADRB1—stomach cancer	0.000473	0.0648	CrCbGaD
Nadolol—Carteolol—ADRB2—stomach cancer	0.000468	0.064	CrCbGaD
Nadolol—Salbutamol—ADRB1—stomach cancer	0.000444	0.0609	CrCbGaD
Nadolol—Penbutolol—ADRB1—stomach cancer	0.000432	0.0592	CrCbGaD
Nadolol—Bupranolol—ADRB2—stomach cancer	0.000398	0.0545	CrCbGaD
Nadolol—Penbutolol—HTR1A—stomach cancer	0.000387	0.053	CrCbGaD
Nadolol—Salbutamol—ADRB2—stomach cancer	0.000374	0.0512	CrCbGaD
Nadolol—Penbutolol—ADRB2—stomach cancer	0.000364	0.0498	CrCbGaD
Nadolol—Pindolol—ADRB1—stomach cancer	0.000312	0.0427	CrCbGaD
Nadolol—Abdominal distension—Capecitabine—stomach cancer	0.0003	0.00243	CcSEcCtD
Nadolol—Pulmonary oedema—Epirubicin—stomach cancer	0.000294	0.00238	CcSEcCtD
Nadolol—Bronchospasm—Capecitabine—stomach cancer	0.000293	0.00237	CcSEcCtD
Nadolol—Fluid retention—Doxorubicin—stomach cancer	0.000291	0.00235	CcSEcCtD
Nadolol—Abdominal discomfort—Capecitabine—stomach cancer	0.000286	0.00231	CcSEcCtD
Nadolol—Dry eye—Doxorubicin—stomach cancer	0.000283	0.00229	CcSEcCtD
Nadolol—Weight increased—Docetaxel—stomach cancer	0.00028	0.00227	CcSEcCtD
Nadolol—Vision blurred—Fluorouracil—stomach cancer	0.00028	0.00227	CcSEcCtD
Nadolol—Pindolol—HTR1A—stomach cancer	0.000279	0.0382	CrCbGaD
Nadolol—Syncope—Irinotecan—stomach cancer	0.000278	0.00225	CcSEcCtD
Nadolol—Loss of consciousness—Irinotecan—stomach cancer	0.000273	0.00221	CcSEcCtD
Nadolol—Pulmonary oedema—Doxorubicin—stomach cancer	0.000272	0.00221	CcSEcCtD
Nadolol—Weight increased—Capecitabine—stomach cancer	0.000271	0.00219	CcSEcCtD
Nadolol—Visual disturbance—Methotrexate—stomach cancer	0.000271	0.00219	CcSEcCtD
Nadolol—Cough—Irinotecan—stomach cancer	0.000271	0.00219	CcSEcCtD
Nadolol—Hypertension—Irinotecan—stomach cancer	0.000268	0.00217	CcSEcCtD
Nadolol—Conjunctivitis—Docetaxel—stomach cancer	0.000267	0.00216	CcSEcCtD
Nadolol—Depression—Capecitabine—stomach cancer	0.000265	0.00214	CcSEcCtD
Nadolol—Cardiac failure congestive—Epirubicin—stomach cancer	0.000265	0.00214	CcSEcCtD
Nadolol—Pindolol—ADRB2—stomach cancer	0.000262	0.0359	CrCbGaD
Nadolol—Lethargy—Methotrexate—stomach cancer	0.000262	0.00212	CcSEcCtD
Nadolol—Conjunctivitis—Capecitabine—stomach cancer	0.000258	0.00209	CcSEcCtD
Nadolol—Agranulocytosis—Docetaxel—stomach cancer	0.000256	0.00207	CcSEcCtD
Nadolol—Oedema—Irinotecan—stomach cancer	0.000253	0.00205	CcSEcCtD
Nadolol—Chest pain—Fluorouracil—stomach cancer	0.000253	0.00205	CcSEcCtD
Nadolol—Shock—Irinotecan—stomach cancer	0.000249	0.00202	CcSEcCtD
Nadolol—Agranulocytosis—Capecitabine—stomach cancer	0.000248	0.00201	CcSEcCtD
Nadolol—Cardiac failure—Epirubicin—stomach cancer	0.000246	0.00199	CcSEcCtD
Nadolol—Lethargy—Epirubicin—stomach cancer	0.000245	0.00198	CcSEcCtD
Nadolol—Cardiac failure congestive—Doxorubicin—stomach cancer	0.000245	0.00198	CcSEcCtD
Nadolol—Irritability—Methotrexate—stomach cancer	0.000245	0.00198	CcSEcCtD
Nadolol—Hyperhidrosis—Irinotecan—stomach cancer	0.000245	0.00198	CcSEcCtD
Nadolol—Mood swings—Methotrexate—stomach cancer	0.000243	0.00197	CcSEcCtD
Nadolol—Bradycardia—Capecitabine—stomach cancer	0.000243	0.00196	CcSEcCtD
Nadolol—Oedema—Fluorouracil—stomach cancer	0.000242	0.00196	CcSEcCtD
Nadolol—Anorexia—Irinotecan—stomach cancer	0.000241	0.00195	CcSEcCtD
Nadolol—Diplopia—Epirubicin—stomach cancer	0.00024	0.00194	CcSEcCtD
Nadolol—Visual impairment—Docetaxel—stomach cancer	0.000237	0.00192	CcSEcCtD
Nadolol—Hypotension—Irinotecan—stomach cancer	0.000237	0.00191	CcSEcCtD
Nadolol—Affect lability—Epirubicin—stomach cancer	0.000236	0.00191	CcSEcCtD
Nadolol—Anorexia—Fluorouracil—stomach cancer	0.000231	0.00187	CcSEcCtD
Nadolol—Visual impairment—Capecitabine—stomach cancer	0.00023	0.00186	CcSEcCtD
Nadolol—Insomnia—Irinotecan—stomach cancer	0.000229	0.00185	CcSEcCtD
Nadolol—Cardiac failure—Doxorubicin—stomach cancer	0.000228	0.00184	CcSEcCtD
Nadolol—Mood swings—Epirubicin—stomach cancer	0.000228	0.00184	CcSEcCtD
Nadolol—Paraesthesia—Irinotecan—stomach cancer	0.000227	0.00184	CcSEcCtD
Nadolol—Lethargy—Doxorubicin—stomach cancer	0.000227	0.00184	CcSEcCtD
Nadolol—Hypotension—Fluorouracil—stomach cancer	0.000227	0.00183	CcSEcCtD
Nadolol—Dyspnoea—Irinotecan—stomach cancer	0.000226	0.00183	CcSEcCtD
Nadolol—Dyspepsia—Irinotecan—stomach cancer	0.000223	0.0018	CcSEcCtD
Nadolol—Tinnitus—Capecitabine—stomach cancer	0.000222	0.0018	CcSEcCtD
Nadolol—Diplopia—Doxorubicin—stomach cancer	0.000222	0.0018	CcSEcCtD
Nadolol—Dry skin—Epirubicin—stomach cancer	0.00022	0.00178	CcSEcCtD
Nadolol—Decreased appetite—Irinotecan—stomach cancer	0.00022	0.00178	CcSEcCtD
Nadolol—Insomnia—Fluorouracil—stomach cancer	0.000219	0.00177	CcSEcCtD
Nadolol—Affect lability—Doxorubicin—stomach cancer	0.000219	0.00177	CcSEcCtD
Nadolol—Fatigue—Irinotecan—stomach cancer	0.000218	0.00177	CcSEcCtD
Nadolol—Paraesthesia—Fluorouracil—stomach cancer	0.000218	0.00176	CcSEcCtD
Nadolol—Alopecia—Docetaxel—stomach cancer	0.000218	0.00176	CcSEcCtD
Nadolol—Constipation—Irinotecan—stomach cancer	0.000216	0.00175	CcSEcCtD
Nadolol—Pain—Irinotecan—stomach cancer	0.000216	0.00175	CcSEcCtD
Nadolol—Dyspnoea—Fluorouracil—stomach cancer	0.000216	0.00175	CcSEcCtD
Nadolol—Dyspepsia—Fluorouracil—stomach cancer	0.000213	0.00173	CcSEcCtD
Nadolol—Abdominal discomfort—Methotrexate—stomach cancer	0.000213	0.00172	CcSEcCtD
Nadolol—Gastritis—Epirubicin—stomach cancer	0.000213	0.00172	CcSEcCtD
Nadolol—Decreased appetite—Fluorouracil—stomach cancer	0.000211	0.00171	CcSEcCtD
Nadolol—Alopecia—Capecitabine—stomach cancer	0.000211	0.00171	CcSEcCtD
Nadolol—Mood swings—Doxorubicin—stomach cancer	0.000211	0.0017	CcSEcCtD
Nadolol—Abdominal distension—Epirubicin—stomach cancer	0.000209	0.00169	CcSEcCtD
Nadolol—Pain—Fluorouracil—stomach cancer	0.000207	0.00168	CcSEcCtD
Nadolol—Flatulence—Capecitabine—stomach cancer	0.000205	0.00166	CcSEcCtD
Nadolol—Erectile dysfunction—Methotrexate—stomach cancer	0.000204	0.00165	CcSEcCtD
Nadolol—Dry skin—Doxorubicin—stomach cancer	0.000204	0.00165	CcSEcCtD
Nadolol—Body temperature increased—Irinotecan—stomach cancer	0.0002	0.00162	CcSEcCtD
Nadolol—Depression—Methotrexate—stomach cancer	0.000197	0.0016	CcSEcCtD
Nadolol—Gastritis—Doxorubicin—stomach cancer	0.000197	0.00159	CcSEcCtD
Nadolol—Vision blurred—Capecitabine—stomach cancer	0.000196	0.00158	CcSEcCtD
Nadolol—Abdominal distension—Doxorubicin—stomach cancer	0.000193	0.00156	CcSEcCtD
Nadolol—Syncope—Docetaxel—stomach cancer	0.000192	0.00156	CcSEcCtD
Nadolol—Conjunctivitis—Methotrexate—stomach cancer	0.000192	0.00156	CcSEcCtD
Nadolol—Body temperature increased—Fluorouracil—stomach cancer	0.000192	0.00155	CcSEcCtD
Nadolol—Sweating—Methotrexate—stomach cancer	0.00019	0.00153	CcSEcCtD
Nadolol—Weight increased—Epirubicin—stomach cancer	0.000189	0.00153	CcSEcCtD
Nadolol—Loss of consciousness—Docetaxel—stomach cancer	0.000188	0.00153	CcSEcCtD
Nadolol—Cough—Docetaxel—stomach cancer	0.000187	0.00151	CcSEcCtD
Nadolol—Syncope—Capecitabine—stomach cancer	0.000186	0.00151	CcSEcCtD
Nadolol—Hypertension—Docetaxel—stomach cancer	0.000185	0.0015	CcSEcCtD
Nadolol—Agranulocytosis—Methotrexate—stomach cancer	0.000185	0.00149	CcSEcCtD
Nadolol—Chest pain—Docetaxel—stomach cancer	0.000183	0.00148	CcSEcCtD
Nadolol—Loss of consciousness—Capecitabine—stomach cancer	0.000182	0.00148	CcSEcCtD
Nadolol—Asthenia—Irinotecan—stomach cancer	0.000182	0.00147	CcSEcCtD
Nadolol—Cough—Capecitabine—stomach cancer	0.000181	0.00147	CcSEcCtD
Nadolol—Conjunctivitis—Epirubicin—stomach cancer	0.00018	0.00146	CcSEcCtD
Nadolol—Hypertension—Capecitabine—stomach cancer	0.000179	0.00145	CcSEcCtD
Nadolol—Dry mouth—Docetaxel—stomach cancer	0.000179	0.00144	CcSEcCtD
Nadolol—Sweating—Epirubicin—stomach cancer	0.000177	0.00144	CcSEcCtD
Nadolol—Chest pain—Capecitabine—stomach cancer	0.000177	0.00143	CcSEcCtD
Nadolol—Oedema—Docetaxel—stomach cancer	0.000175	0.00142	CcSEcCtD
Nadolol—Weight increased—Doxorubicin—stomach cancer	0.000175	0.00141	CcSEcCtD
Nadolol—Diarrhoea—Irinotecan—stomach cancer	0.000173	0.0014	CcSEcCtD
Nadolol—Dry mouth—Capecitabine—stomach cancer	0.000173	0.0014	CcSEcCtD
Nadolol—Agranulocytosis—Epirubicin—stomach cancer	0.000173	0.0014	CcSEcCtD
Nadolol—Shock—Docetaxel—stomach cancer	0.000172	0.00139	CcSEcCtD
Nadolol—Pruritus—Fluorouracil—stomach cancer	0.000172	0.00139	CcSEcCtD
Nadolol—Visual impairment—Methotrexate—stomach cancer	0.000171	0.00138	CcSEcCtD
Nadolol—Oedema—Capecitabine—stomach cancer	0.000169	0.00137	CcSEcCtD
Nadolol—Bradycardia—Epirubicin—stomach cancer	0.000169	0.00137	CcSEcCtD
Nadolol—Dizziness—Irinotecan—stomach cancer	0.000167	0.00135	CcSEcCtD
Nadolol—Anorexia—Docetaxel—stomach cancer	0.000167	0.00135	CcSEcCtD
Nadolol—Shock—Capecitabine—stomach cancer	0.000167	0.00135	CcSEcCtD
Nadolol—Conjunctivitis—Doxorubicin—stomach cancer	0.000166	0.00135	CcSEcCtD
Nadolol—Diarrhoea—Fluorouracil—stomach cancer	0.000166	0.00134	CcSEcCtD
Nadolol—Tinnitus—Methotrexate—stomach cancer	0.000166	0.00134	CcSEcCtD
Nadolol—Sweating—Doxorubicin—stomach cancer	0.000164	0.00133	CcSEcCtD
Nadolol—Hyperhidrosis—Capecitabine—stomach cancer	0.000164	0.00133	CcSEcCtD
Nadolol—Hypotension—Docetaxel—stomach cancer	0.000164	0.00132	CcSEcCtD
Nadolol—Anorexia—Capecitabine—stomach cancer	0.000162	0.00131	CcSEcCtD
Nadolol—Vomiting—Irinotecan—stomach cancer	0.000161	0.0013	CcSEcCtD
Nadolol—Dizziness—Fluorouracil—stomach cancer	0.00016	0.0013	CcSEcCtD
Nadolol—Visual impairment—Epirubicin—stomach cancer	0.00016	0.0013	CcSEcCtD
Nadolol—Agranulocytosis—Doxorubicin—stomach cancer	0.00016	0.00129	CcSEcCtD
Nadolol—Rash—Irinotecan—stomach cancer	0.00016	0.00129	CcSEcCtD
Nadolol—Dermatitis—Irinotecan—stomach cancer	0.000159	0.00129	CcSEcCtD
Nadolol—Hypotension—Capecitabine—stomach cancer	0.000158	0.00128	CcSEcCtD
Nadolol—Insomnia—Docetaxel—stomach cancer	0.000158	0.00128	CcSEcCtD
Nadolol—Paraesthesia—Docetaxel—stomach cancer	0.000157	0.00127	CcSEcCtD
Nadolol—Alopecia—Methotrexate—stomach cancer	0.000157	0.00127	CcSEcCtD
Nadolol—Bradycardia—Doxorubicin—stomach cancer	0.000157	0.00127	CcSEcCtD
Nadolol—Dyspnoea—Docetaxel—stomach cancer	0.000156	0.00126	CcSEcCtD
Nadolol—Tinnitus—Epirubicin—stomach cancer	0.000155	0.00125	CcSEcCtD
Nadolol—Vomiting—Fluorouracil—stomach cancer	0.000154	0.00125	CcSEcCtD
Nadolol—Dyspepsia—Docetaxel—stomach cancer	0.000154	0.00125	CcSEcCtD
Nadolol—Insomnia—Capecitabine—stomach cancer	0.000153	0.00124	CcSEcCtD
Nadolol—Rash—Fluorouracil—stomach cancer	0.000153	0.00124	CcSEcCtD
Nadolol—Dermatitis—Fluorouracil—stomach cancer	0.000153	0.00124	CcSEcCtD
Nadolol—Paraesthesia—Capecitabine—stomach cancer	0.000152	0.00123	CcSEcCtD
Nadolol—Decreased appetite—Docetaxel—stomach cancer	0.000152	0.00123	CcSEcCtD
Nadolol—Dyspnoea—Capecitabine—stomach cancer	0.000151	0.00122	CcSEcCtD
Nadolol—Fatigue—Docetaxel—stomach cancer	0.000151	0.00122	CcSEcCtD
Nadolol—Nausea—Irinotecan—stomach cancer	0.00015	0.00122	CcSEcCtD
Nadolol—Pain—Docetaxel—stomach cancer	0.00015	0.00121	CcSEcCtD
Nadolol—Constipation—Docetaxel—stomach cancer	0.00015	0.00121	CcSEcCtD
Nadolol—Dyspepsia—Capecitabine—stomach cancer	0.000149	0.00121	CcSEcCtD
Nadolol—Visual impairment—Doxorubicin—stomach cancer	0.000148	0.0012	CcSEcCtD
Nadolol—Decreased appetite—Capecitabine—stomach cancer	0.000147	0.00119	CcSEcCtD
Nadolol—Alopecia—Epirubicin—stomach cancer	0.000147	0.00119	CcSEcCtD
Nadolol—Fatigue—Capecitabine—stomach cancer	0.000146	0.00118	CcSEcCtD
Nadolol—Vision blurred—Methotrexate—stomach cancer	0.000146	0.00118	CcSEcCtD
Nadolol—Constipation—Capecitabine—stomach cancer	0.000145	0.00117	CcSEcCtD
Nadolol—Pain—Capecitabine—stomach cancer	0.000145	0.00117	CcSEcCtD
Nadolol—Nausea—Fluorouracil—stomach cancer	0.000144	0.00117	CcSEcCtD
Nadolol—Tinnitus—Doxorubicin—stomach cancer	0.000143	0.00116	CcSEcCtD
Nadolol—Flatulence—Epirubicin—stomach cancer	0.000143	0.00115	CcSEcCtD
Nadolol—Body temperature increased—Docetaxel—stomach cancer	0.000138	0.00112	CcSEcCtD
Nadolol—Vision blurred—Epirubicin—stomach cancer	0.000136	0.0011	CcSEcCtD
Nadolol—Alopecia—Doxorubicin—stomach cancer	0.000136	0.0011	CcSEcCtD
Nadolol—Cough—Methotrexate—stomach cancer	0.000135	0.00109	CcSEcCtD
Nadolol—Body temperature increased—Capecitabine—stomach cancer	0.000134	0.00108	CcSEcCtD
Nadolol—Flatulence—Doxorubicin—stomach cancer	0.000132	0.00107	CcSEcCtD
Nadolol—Chest pain—Methotrexate—stomach cancer	0.000132	0.00106	CcSEcCtD
Nadolol—Syncope—Epirubicin—stomach cancer	0.00013	0.00105	CcSEcCtD
Nadolol—Loss of consciousness—Epirubicin—stomach cancer	0.000127	0.00103	CcSEcCtD
Nadolol—Cough—Epirubicin—stomach cancer	0.000126	0.00102	CcSEcCtD
Nadolol—Vision blurred—Doxorubicin—stomach cancer	0.000126	0.00102	CcSEcCtD
Nadolol—Asthenia—Docetaxel—stomach cancer	0.000126	0.00102	CcSEcCtD
Nadolol—Hypertension—Epirubicin—stomach cancer	0.000125	0.00101	CcSEcCtD
Nadolol—Pruritus—Docetaxel—stomach cancer	0.000124	0.001	CcSEcCtD
Nadolol—Chest pain—Epirubicin—stomach cancer	0.000123	0.000996	CcSEcCtD
Nadolol—Hyperhidrosis—Methotrexate—stomach cancer	0.000122	0.000987	CcSEcCtD
Nadolol—Asthenia—Capecitabine—stomach cancer	0.000122	0.000984	CcSEcCtD
Nadolol—Dry mouth—Epirubicin—stomach cancer	0.00012	0.000974	CcSEcCtD
Nadolol—Anorexia—Methotrexate—stomach cancer	0.00012	0.000973	CcSEcCtD
Nadolol—Syncope—Doxorubicin—stomach cancer	0.00012	0.000971	CcSEcCtD
Nadolol—Pruritus—Capecitabine—stomach cancer	0.00012	0.00097	CcSEcCtD
Nadolol—Diarrhoea—Docetaxel—stomach cancer	0.00012	0.000969	CcSEcCtD
Nadolol—Oedema—Epirubicin—stomach cancer	0.000118	0.000955	CcSEcCtD
Nadolol—Hypotension—Methotrexate—stomach cancer	0.000118	0.000954	CcSEcCtD
Nadolol—Loss of consciousness—Doxorubicin—stomach cancer	0.000118	0.000952	CcSEcCtD
Nadolol—Cough—Doxorubicin—stomach cancer	0.000117	0.000945	CcSEcCtD
Nadolol—Shock—Epirubicin—stomach cancer	0.000116	0.00094	CcSEcCtD
Nadolol—Diarrhoea—Capecitabine—stomach cancer	0.000116	0.000938	CcSEcCtD
Nadolol—Dizziness—Docetaxel—stomach cancer	0.000116	0.000936	CcSEcCtD
Nadolol—Hypertension—Doxorubicin—stomach cancer	0.000116	0.000935	CcSEcCtD
Nadolol—Hyperhidrosis—Epirubicin—stomach cancer	0.000114	0.000923	CcSEcCtD
Nadolol—Insomnia—Methotrexate—stomach cancer	0.000114	0.000923	CcSEcCtD
Nadolol—Chest pain—Doxorubicin—stomach cancer	0.000114	0.000922	CcSEcCtD
Nadolol—Paraesthesia—Methotrexate—stomach cancer	0.000113	0.000917	CcSEcCtD
Nadolol—Anorexia—Epirubicin—stomach cancer	0.000113	0.000911	CcSEcCtD
Nadolol—Dyspnoea—Methotrexate—stomach cancer	0.000112	0.00091	CcSEcCtD
Nadolol—Dizziness—Capecitabine—stomach cancer	0.000112	0.000907	CcSEcCtD
Nadolol—Dry mouth—Doxorubicin—stomach cancer	0.000111	0.000902	CcSEcCtD
Nadolol—Vomiting—Docetaxel—stomach cancer	0.000111	0.0009	CcSEcCtD
Nadolol—Dyspepsia—Methotrexate—stomach cancer	0.000111	0.000898	CcSEcCtD
Nadolol—Rash—Docetaxel—stomach cancer	0.00011	0.000893	CcSEcCtD
Nadolol—Hypotension—Epirubicin—stomach cancer	0.00011	0.000893	CcSEcCtD
Nadolol—Dermatitis—Docetaxel—stomach cancer	0.00011	0.000892	CcSEcCtD
Nadolol—Decreased appetite—Methotrexate—stomach cancer	0.00011	0.000887	CcSEcCtD
Nadolol—Oedema—Doxorubicin—stomach cancer	0.000109	0.000884	CcSEcCtD
Nadolol—Fatigue—Methotrexate—stomach cancer	0.000109	0.00088	CcSEcCtD
Nadolol—Pain—Methotrexate—stomach cancer	0.000108	0.000873	CcSEcCtD
Nadolol—Vomiting—Capecitabine—stomach cancer	0.000108	0.000872	CcSEcCtD
Nadolol—Shock—Doxorubicin—stomach cancer	0.000107	0.00087	CcSEcCtD
Nadolol—Rash—Capecitabine—stomach cancer	0.000107	0.000865	CcSEcCtD
Nadolol—Insomnia—Epirubicin—stomach cancer	0.000107	0.000864	CcSEcCtD
Nadolol—Dermatitis—Capecitabine—stomach cancer	0.000107	0.000864	CcSEcCtD
Nadolol—Paraesthesia—Epirubicin—stomach cancer	0.000106	0.000858	CcSEcCtD
Nadolol—Hyperhidrosis—Doxorubicin—stomach cancer	0.000106	0.000854	CcSEcCtD
Nadolol—Dyspnoea—Epirubicin—stomach cancer	0.000105	0.000852	CcSEcCtD
Nadolol—Anorexia—Doxorubicin—stomach cancer	0.000104	0.000842	CcSEcCtD
Nadolol—Nausea—Docetaxel—stomach cancer	0.000104	0.000841	CcSEcCtD
Nadolol—Dyspepsia—Epirubicin—stomach cancer	0.000104	0.000841	CcSEcCtD
Nadolol—Decreased appetite—Epirubicin—stomach cancer	0.000103	0.00083	CcSEcCtD
Nadolol—Hypotension—Doxorubicin—stomach cancer	0.000102	0.000826	CcSEcCtD
Nadolol—Fatigue—Epirubicin—stomach cancer	0.000102	0.000824	CcSEcCtD
Nadolol—Pain—Epirubicin—stomach cancer	0.000101	0.000817	CcSEcCtD
Nadolol—Constipation—Epirubicin—stomach cancer	0.000101	0.000817	CcSEcCtD
Nadolol—Nausea—Capecitabine—stomach cancer	0.000101	0.000814	CcSEcCtD
Nadolol—Body temperature increased—Methotrexate—stomach cancer	9.97e-05	0.000807	CcSEcCtD
Nadolol—Insomnia—Doxorubicin—stomach cancer	9.88e-05	0.000799	CcSEcCtD
Nadolol—Paraesthesia—Doxorubicin—stomach cancer	9.81e-05	0.000794	CcSEcCtD
Nadolol—Dyspnoea—Doxorubicin—stomach cancer	9.74e-05	0.000788	CcSEcCtD
Nadolol—Dyspepsia—Doxorubicin—stomach cancer	9.61e-05	0.000778	CcSEcCtD
Nadolol—Decreased appetite—Doxorubicin—stomach cancer	9.49e-05	0.000768	CcSEcCtD
Nadolol—Fatigue—Doxorubicin—stomach cancer	9.42e-05	0.000762	CcSEcCtD
Nadolol—Pain—Doxorubicin—stomach cancer	9.34e-05	0.000756	CcSEcCtD
Nadolol—Constipation—Doxorubicin—stomach cancer	9.34e-05	0.000756	CcSEcCtD
Nadolol—Body temperature increased—Epirubicin—stomach cancer	9.33e-05	0.000755	CcSEcCtD
Nadolol—Asthenia—Methotrexate—stomach cancer	9.05e-05	0.000732	CcSEcCtD
Nadolol—Pruritus—Methotrexate—stomach cancer	8.92e-05	0.000722	CcSEcCtD
Nadolol—Body temperature increased—Doxorubicin—stomach cancer	8.63e-05	0.000699	CcSEcCtD
Nadolol—Diarrhoea—Methotrexate—stomach cancer	8.63e-05	0.000698	CcSEcCtD
Nadolol—Asthenia—Epirubicin—stomach cancer	8.47e-05	0.000685	CcSEcCtD
Nadolol—Pruritus—Epirubicin—stomach cancer	8.35e-05	0.000676	CcSEcCtD
Nadolol—Dizziness—Methotrexate—stomach cancer	8.34e-05	0.000675	CcSEcCtD
Nadolol—Diarrhoea—Epirubicin—stomach cancer	8.08e-05	0.000654	CcSEcCtD
Nadolol—Vomiting—Methotrexate—stomach cancer	8.02e-05	0.000649	CcSEcCtD
Nadolol—Rash—Methotrexate—stomach cancer	7.95e-05	0.000644	CcSEcCtD
Nadolol—Dermatitis—Methotrexate—stomach cancer	7.95e-05	0.000643	CcSEcCtD
Nadolol—Asthenia—Doxorubicin—stomach cancer	7.84e-05	0.000634	CcSEcCtD
Nadolol—Dizziness—Epirubicin—stomach cancer	7.81e-05	0.000632	CcSEcCtD
Nadolol—Pruritus—Doxorubicin—stomach cancer	7.73e-05	0.000625	CcSEcCtD
Nadolol—Vomiting—Epirubicin—stomach cancer	7.51e-05	0.000607	CcSEcCtD
Nadolol—Nausea—Methotrexate—stomach cancer	7.49e-05	0.000606	CcSEcCtD
Nadolol—Diarrhoea—Doxorubicin—stomach cancer	7.47e-05	0.000605	CcSEcCtD
Nadolol—Rash—Epirubicin—stomach cancer	7.44e-05	0.000602	CcSEcCtD
Nadolol—Dermatitis—Epirubicin—stomach cancer	7.44e-05	0.000602	CcSEcCtD
Nadolol—Dizziness—Doxorubicin—stomach cancer	7.22e-05	0.000584	CcSEcCtD
Nadolol—Nausea—Epirubicin—stomach cancer	7.01e-05	0.000567	CcSEcCtD
Nadolol—Vomiting—Doxorubicin—stomach cancer	6.94e-05	0.000562	CcSEcCtD
Nadolol—Rash—Doxorubicin—stomach cancer	6.89e-05	0.000557	CcSEcCtD
Nadolol—Dermatitis—Doxorubicin—stomach cancer	6.88e-05	0.000557	CcSEcCtD
Nadolol—Nausea—Doxorubicin—stomach cancer	6.49e-05	0.000525	CcSEcCtD
Nadolol—ABCB1—Metabolism—BLVRB—stomach cancer	2.33e-05	0.000673	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PGLS—stomach cancer	2.33e-05	0.000673	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RPS6—stomach cancer	2.28e-05	0.000659	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PRKCB—stomach cancer	2.24e-05	0.000648	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6ST—stomach cancer	2.23e-05	0.000646	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPAP2A—stomach cancer	2.22e-05	0.000642	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FST—stomach cancer	2.15e-05	0.000622	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADRB2—stomach cancer	2.14e-05	0.000618	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HBEGF—stomach cancer	2.11e-05	0.000608	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FST—stomach cancer	2.11e-05	0.000608	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HBEGF—stomach cancer	2.1e-05	0.000605	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RGS2—stomach cancer	2.08e-05	0.0006	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GAST—stomach cancer	2.08e-05	0.0006	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HBEGF—stomach cancer	2.06e-05	0.000595	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GAST—stomach cancer	2.03e-05	0.000587	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RGS2—stomach cancer	2.03e-05	0.000587	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6R—stomach cancer	1.99e-05	0.000576	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—RHOA—stomach cancer	1.98e-05	0.000573	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CA1—stomach cancer	1.98e-05	0.000572	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—FBP1—stomach cancer	1.98e-05	0.000572	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NDUFA2—stomach cancer	1.98e-05	0.000572	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CKB—stomach cancer	1.98e-05	0.000572	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGG—stomach cancer	1.97e-05	0.000569	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—stomach cancer	1.95e-05	0.000565	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADRB2—stomach cancer	1.94e-05	0.000561	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADRB2—stomach cancer	1.93e-05	0.000559	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGG—stomach cancer	1.93e-05	0.000556	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—stomach cancer	1.91e-05	0.000552	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PPP2R1A—stomach cancer	1.9e-05	0.00055	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PPP2R1A—stomach cancer	1.9e-05	0.000547	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKAA1—stomach cancer	1.89e-05	0.000547	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PPP2R1A—stomach cancer	1.86e-05	0.000538	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PLIN2—stomach cancer	1.86e-05	0.000538	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKAA1—stomach cancer	1.85e-05	0.000535	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RBP4—stomach cancer	1.83e-05	0.000529	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL8—stomach cancer	1.83e-05	0.000528	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CA2—stomach cancer	1.81e-05	0.000523	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—stomach cancer	1.81e-05	0.000523	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—RHOA—stomach cancer	1.8e-05	0.00052	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RBP4—stomach cancer	1.79e-05	0.000517	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL8—stomach cancer	1.79e-05	0.000517	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PGAM1—stomach cancer	1.77e-05	0.00051	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NT5E—stomach cancer	1.77e-05	0.00051	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SMAD4—stomach cancer	1.76e-05	0.000508	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL8—stomach cancer	1.74e-05	0.000503	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—stomach cancer	1.73e-05	0.000499	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—stomach cancer	1.72e-05	0.000498	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALDH7A1—stomach cancer	1.68e-05	0.000486	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PLCE1—stomach cancer	1.68e-05	0.000486	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FYN—stomach cancer	1.67e-05	0.000483	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—stomach cancer	1.67e-05	0.000482	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—stomach cancer	1.63e-05	0.000471	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—UMPS—stomach cancer	1.61e-05	0.000466	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL8—stomach cancer	1.58e-05	0.000457	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HSPB1—stomach cancer	1.57e-05	0.000455	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGTR2—stomach cancer	1.57e-05	0.000455	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FGFR2—stomach cancer	1.57e-05	0.000453	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BMP2—stomach cancer	1.56e-05	0.000449	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—F2R—stomach cancer	1.56e-05	0.000449	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGTR2—stomach cancer	1.54e-05	0.000445	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HSPB1—stomach cancer	1.54e-05	0.000445	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKR1C3—stomach cancer	1.53e-05	0.000442	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—F2R—stomach cancer	1.52e-05	0.00044	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BMP2—stomach cancer	1.52e-05	0.00044	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HTR1A—stomach cancer	1.51e-05	0.000438	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—stomach cancer	1.51e-05	0.000435	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ECHS1—stomach cancer	1.5e-05	0.000434	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PDHA1—stomach cancer	1.5e-05	0.000434	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKR1C3—stomach cancer	1.5e-05	0.000433	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HTR1A—stomach cancer	1.48e-05	0.000428	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PRKCB—stomach cancer	1.47e-05	0.000424	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ANXA1—stomach cancer	1.46e-05	0.000423	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—HMOX1—stomach cancer	1.44e-05	0.000417	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS2—stomach cancer	1.44e-05	0.000415	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PRKCB—stomach cancer	1.43e-05	0.000414	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ANXA1—stomach cancer	1.43e-05	0.000413	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—stomach cancer	1.42e-05	0.000411	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TYMP—stomach cancer	1.41e-05	0.000408	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—FADS1—stomach cancer	1.41e-05	0.000408	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CAV1—stomach cancer	1.39e-05	0.000402	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOA1—stomach cancer	1.39e-05	0.000401	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADRB1—stomach cancer	1.39e-05	0.0004	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—stomach cancer	1.39e-05	0.0004	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—stomach cancer	1.35e-05	0.000391	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—stomach cancer	1.35e-05	0.000391	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RPS6—stomach cancer	1.35e-05	0.000391	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PRKCB—stomach cancer	1.33e-05	0.000385	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6ST—stomach cancer	1.33e-05	0.000383	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PRKCB—stomach cancer	1.33e-05	0.000383	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RPS6—stomach cancer	1.32e-05	0.000382	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SREBF2—stomach cancer	1.32e-05	0.000382	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6ST—stomach cancer	1.32e-05	0.000381	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—RORA—stomach cancer	1.31e-05	0.000377	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PRKCB—stomach cancer	1.3e-05	0.000376	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6ST—stomach cancer	1.3e-05	0.000375	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—stomach cancer	1.29e-05	0.000373	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—stomach cancer	1.28e-05	0.00037	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APC—stomach cancer	1.27e-05	0.000366	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HBEGF—stomach cancer	1.24e-05	0.000359	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALDOB—stomach cancer	1.22e-05	0.000353	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HBEGF—stomach cancer	1.22e-05	0.000351	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MAPK3—stomach cancer	1.21e-05	0.000351	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6R—stomach cancer	1.18e-05	0.000342	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6R—stomach cancer	1.18e-05	0.00034	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—RHOA—stomach cancer	1.18e-05	0.00034	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—stomach cancer	1.18e-05	0.00034	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6R—stomach cancer	1.16e-05	0.000334	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MAPK1—stomach cancer	1.16e-05	0.000334	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—stomach cancer	1.16e-05	0.000334	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—RHOA—stomach cancer	1.15e-05	0.000333	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRB2—stomach cancer	1.15e-05	0.000332	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALOX5—stomach cancer	1.14e-05	0.000329	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—stomach cancer	1.14e-05	0.000329	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PPP2R1A—stomach cancer	1.12e-05	0.000325	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—DPYD—stomach cancer	1.12e-05	0.000323	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—stomach cancer	1.1e-05	0.000319	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SERPINE1—stomach cancer	1.1e-05	0.000319	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PPP2R1A—stomach cancer	1.1e-05	0.000318	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—APOA1—stomach cancer	1.09e-05	0.000316	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—KRAS—stomach cancer	1.09e-05	0.000315	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—RHOA—stomach cancer	1.07e-05	0.000309	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RHOA—stomach cancer	1.06e-05	0.000307	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOS3—stomach cancer	1.05e-05	0.000304	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—RHOA—stomach cancer	1.05e-05	0.000302	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SMAD4—stomach cancer	1.04e-05	0.000302	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL8—stomach cancer	1.03e-05	0.000299	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SMAD4—stomach cancer	1.02e-05	0.000295	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL8—stomach cancer	1.01e-05	0.000292	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—stomach cancer	1e-05	0.00029	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FYN—stomach cancer	9.92e-06	0.000286	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTT1—stomach cancer	9.9e-06	0.000286	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ERBB2—stomach cancer	9.85e-06	0.000285	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2A6—stomach cancer	9.78e-06	0.000283	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FYN—stomach cancer	9.7e-06	0.00028	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKR1C3—stomach cancer	9.52e-06	0.000275	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL8—stomach cancer	9.39e-06	0.000271	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL8—stomach cancer	9.34e-06	0.00027	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGFR2—stomach cancer	9.31e-06	0.000269	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—HRAS—stomach cancer	9.28e-06	0.000268	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ENO1—stomach cancer	9.27e-06	0.000268	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL8—stomach cancer	9.18e-06	0.000265	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1B—stomach cancer	9.12e-06	0.000263	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGFR2—stomach cancer	9.11e-06	0.000263	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—stomach cancer	8.88e-06	0.000257	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCND1—stomach cancer	8.7e-06	0.000251	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—JUN—stomach cancer	8.68e-06	0.000251	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	8.67e-06	0.000251	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS2—stomach cancer	8.53e-06	0.000246	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—stomach cancer	8.45e-06	0.000244	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1A—stomach cancer	8.42e-06	0.000243	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS2—stomach cancer	8.34e-06	0.000241	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CAV1—stomach cancer	8.27e-06	0.000239	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOA1—stomach cancer	8.25e-06	0.000238	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD44—stomach cancer	8.23e-06	0.000238	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK8—stomach cancer	8.22e-06	0.000237	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CAV1—stomach cancer	8.09e-06	0.000234	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOA1—stomach cancer	8.07e-06	0.000233	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCB—stomach cancer	7.87e-06	0.000227	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6ST—stomach cancer	7.84e-06	0.000226	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCB—stomach cancer	7.7e-06	0.000222	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6ST—stomach cancer	7.67e-06	0.000221	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—stomach cancer	7.59e-06	0.000219	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APC—stomach cancer	7.53e-06	0.000217	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—stomach cancer	7.51e-06	0.000217	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APC—stomach cancer	7.37e-06	0.000213	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK3—stomach cancer	7.21e-06	0.000208	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK3—stomach cancer	7.18e-06	0.000207	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK3—stomach cancer	7.05e-06	0.000204	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPP2R1A—stomach cancer	6.99e-06	0.000202	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6R—stomach cancer	6.99e-06	0.000202	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—stomach cancer	6.98e-06	0.000202	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK1—stomach cancer	6.86e-06	0.000198	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTP1—stomach cancer	6.86e-06	0.000198	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—stomach cancer	6.86e-06	0.000198	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6R—stomach cancer	6.84e-06	0.000198	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK1—stomach cancer	6.83e-06	0.000197	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—stomach cancer	6.83e-06	0.000197	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMOX1—stomach cancer	6.77e-06	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK1—stomach cancer	6.71e-06	0.000194	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—stomach cancer	6.71e-06	0.000194	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—stomach cancer	6.56e-06	0.000189	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SERPINE1—stomach cancer	6.55e-06	0.000189	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—KRAS—stomach cancer	6.48e-06	0.000187	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KRAS—stomach cancer	6.45e-06	0.000186	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—stomach cancer	6.41e-06	0.000185	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SERPINE1—stomach cancer	6.4e-06	0.000185	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TYMS—stomach cancer	6.38e-06	0.000184	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—KRAS—stomach cancer	6.34e-06	0.000183	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RHOA—stomach cancer	6.32e-06	0.000182	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTM1—stomach cancer	6.3e-06	0.000182	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOS3—stomach cancer	6.25e-06	0.000181	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RHOA—stomach cancer	6.18e-06	0.000178	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOS3—stomach cancer	6.11e-06	0.000177	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—stomach cancer	5.95e-06	0.000172	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ERCC2—stomach cancer	5.93e-06	0.000171	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—stomach cancer	5.93e-06	0.000171	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB2—stomach cancer	5.85e-06	0.000169	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—stomach cancer	5.82e-06	0.000168	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—stomach cancer	5.73e-06	0.000166	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB2—stomach cancer	5.72e-06	0.000165	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—stomach cancer	5.57e-06	0.000161	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL8—stomach cancer	5.54e-06	0.00016	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HRAS—stomach cancer	5.51e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HRAS—stomach cancer	5.48e-06	0.000158	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL8—stomach cancer	5.42e-06	0.000157	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1B—stomach cancer	5.41e-06	0.000156	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HRAS—stomach cancer	5.39e-06	0.000156	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1B—stomach cancer	5.3e-06	0.000153	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—stomach cancer	5.27e-06	0.000152	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—stomach cancer	5.25e-06	0.000152	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCND1—stomach cancer	5.17e-06	0.000149	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—stomach cancer	5.16e-06	0.000149	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JUN—stomach cancer	5.15e-06	0.000149	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CAV1—stomach cancer	5.14e-06	0.000148	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA1—stomach cancer	5.13e-06	0.000148	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCND1—stomach cancer	5.05e-06	0.000146	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JUN—stomach cancer	5.04e-06	0.000146	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—stomach cancer	5.01e-06	0.000145	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1A—stomach cancer	5e-06	0.000144	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—stomach cancer	4.91e-06	0.000142	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1A—stomach cancer	4.89e-06	0.000141	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK8—stomach cancer	4.88e-06	0.000141	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK8—stomach cancer	4.77e-06	0.000138	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARG—stomach cancer	4.52e-06	0.00013	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—stomach cancer	4.5e-06	0.00013	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—stomach cancer	4.46e-06	0.000129	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—stomach cancer	4.4e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—stomach cancer	4.36e-06	0.000126	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK3—stomach cancer	4.26e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK3—stomach cancer	4.17e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—stomach cancer	4.14e-06	0.00012	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—stomach cancer	4.06e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK1—stomach cancer	4.05e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—stomach cancer	4.05e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—stomach cancer	4.05e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK1—stomach cancer	3.96e-06	0.000115	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—stomach cancer	3.96e-06	0.000114	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NOS3—stomach cancer	3.89e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KRAS—stomach cancer	3.83e-06	0.000111	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KRAS—stomach cancer	3.74e-06	0.000108	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—stomach cancer	3.55e-06	0.000103	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—stomach cancer	3.52e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—stomach cancer	3.44e-06	9.94e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—stomach cancer	3.4e-06	9.83e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—stomach cancer	3.33e-06	9.61e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HRAS—stomach cancer	3.25e-06	9.4e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HRAS—stomach cancer	3.18e-06	9.19e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—stomach cancer	3.11e-06	9e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—stomach cancer	3.05e-06	8.8e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—stomach cancer	2.19e-06	6.32e-05	CbGpPWpGaD
